Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer

作     者：Ning Shao Wo Zhu Fang-Ning Wan Ding-Wei Ye 

作者机构：Department of UrologyFudan University Shanghai Cancer CenterShanghai 200032China Department of OncologyShanghai Medical CollegeFudan UniversityShanghai 200032China. 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2019年第21卷第6期

页      面：618-622页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This study was supported by the National Natural Science Foundation of China(No.81502192 to FNW,No.81370073 to YZ and No.81872099,81472377 and 81672544 to DWY) the Shanghai Rising Star Program(No.16QA1401100) 

主　　题：biochemical recurrence biomarker high risk Iong noncoding RNA prostate cancer 

摘      要：Accumulating evidenee suggested that long noncoding RNAs(IncRNAs)possess a potential role in prostate cancer(PCa)diagnosis and *** biochemical recurrence(BCR)is considered as a sign for clinical recurrence metastasis and PCa-specific ***,the aim of the present study was to identify a IncRNA signature that can predict BCR of PCa *** analysis,Kaplan-Meier analyses,Cox regression analyses,and Gene Set Enrichment Analysis(GSEA)were performed in a publicly available database with 499 PCa tissues and 52 matched normal tissues.A signature was *** these IncRNAs were differentially expressed between tumor and normal tissues and differentially expressed between high Gleason score and low Gleason score ***,we developed a seven IncRNAs signature that can predict PCa *** classified into low-risk group showed better BCR survival significantly than the patients in the high-risk group(hazard ratio=0.32,95%Cl:0.20-0.52,concordance index=0.63).The area under the curve was 0.68 for *** signature also had good discrimination for BCR in men with Gleason 7 *** conclusion,our results suggest that the seven IncRNAs signature is a new biomarker of BCR and high risk in *** addition,the in dividual In cRNA warrants further study to un cover the associated mechanisms of PCa progression and the signature could be used to design direct clinical trials for adjuvant therapy.